2025. Flexible Dosing of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis: Initial Results From the Real-World–Simulating Expanded Access Protocol Study, JADE REAL. SKIN The Journal of Cutaneous Medicine. 9, 6 (Nov. 2025), s618. DOI:https://doi.org/10.25251/t4rkzz84.